Latest total assets for FLXN: $220M.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
Flexion Therapeutics posts a total assets of $220M as of September 2021. That compares with $260M in the prior-year period — down 17.3% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.
In the prior comparable period, Flexion Therapeutics's total assets was $260M. The latest reading is $220M — a 17.3% year-over-year decrease (period ending September 2021). Use the history and growth charts on this page for a longer lookback.
Total Assets is one piece of Flexion Therapeutics's financial statement story. At $220M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.
Context for FLXN's total assets usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Flexion Therapeutics's other metric pages and overview cover the third.
Judging Flexion Therapeutics against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in total assets easier to interpret. Start with $220M here, then scan peer and history charts to see if the gap is persistent.